Pfizer was sued by the US Texas prosecutor for "improperly stating the effectiveness of COVID-19 vaccine"
白云追月素
发表于 2023-12-1 10:09:58
300
0
0
[Accused by the US Texas prosecutor of "improperly stating the effectiveness of COVID-19 vaccine" Pfizer responded.] On November 30 local time, the US Texas Attorney General Paxton sued Pfizer, accusing the company of improperly stating the effectiveness of COVID-19 vaccine, requiring the judge of the Texas court to impose a fine of more than 10 million dollars, and ordered Pfizer not to publicly discuss the effectiveness of its vaccine. Pfizer said that the company "places the safety and effectiveness of therapeutic drugs and vaccines at the highest level, and the company's statement on its COVID-19 vaccine is accurate and scientifically based".
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
- The number of employees in Starbucks' US stores continues to decline due to the policy of 'adding stores but not adding people'
- Black Friday Quick Report: Online and offline online shopping in the United States is expected to set a new record!
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Delaware judge overturns Musk salary agreement, Tesla says it will appeal
- Tesla surged last night! Bank of America raises Tesla's 12-month target price to $400 and maintains buy rating
- Weekly Outlook | US CPI may shake expectations of Fed interest rate cuts! Oracle and Broadcom announce their performance, will it affect the subsequent trend of AI concept stocks?
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- The US warehouse strike poses challenges to Amazon's holiday shopping season operations
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy